{"commentary":{"count":39,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":15,"x_thread":14,"podcast":10},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01926236\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ABC06","nct_id":"NCT01926236","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=abc06-nct01926236. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ABC06","arms":[{"description":"Active Symptom Control","label":"Arm A: Active symptom control (ASC)","type":"ACTIVE_COMPARATOR"},{"description":"Active Symptom Control with OxMdG chemo (Oxaliplatin, L-folinic acid \\& 5FU)","label":"Arm B: ASC with OxMdG chemotherapy","type":"EXPERIMENTAL"}],"collaborators":["Cancer Research UK"],"completion_date":{"date":"2019-01","type":"ACTUAL"},"conditions":["Biliary Tract Cancer","Gallbladder Cancer","Cholangiocarcinoma","Ampullary Cancer"],"enrollment":{"count":162,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Active Symptom Control","type":"OTHER"},{"name":"L-folinic acid","type":"DRUG"},{"name":"5 FU","type":"DRUG"},{"name":"Oxaliplatin","type":"DRUG"}],"last_update":"2020-01-28","lead_sponsor":"The Christie NHS Foundation Trust","official_title":"A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2018-01-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"Evaluated by monthly follow-up until 12 months after last patient included"}],"references":[{"citation":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, Falk S, Gillmore R, Wadsley J, Patel K, Anthoney A, Maraveyas A, Iveson T, Waters JS, Hobbs C, Barber S, Ryder WD, Ramage J, Davies LM, Bridgewater JA, Valle JW; Advanced Biliary Cancer Working Group. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021 May;22(5):690-701. doi: 10.1016/S1470-2045(21)00027-9. Epub 2021 Mar 30.","pmid":"33798493","type":"DERIVED"}],"start_date":{"date":"2014-02"},"study_type":"INTERVENTIONAL","title":"Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers","url":"https://clinicaltrials.gov/study/NCT01926236"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/abc06-nct01926236"}